PubMed Health⌕ Search

Biomedical subjects

Robert P Thomas

Publications and source records attributed to Robert P Thomas.

8 recordsLinked to original sources
PubMed2004

Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas.

BACKGROUND/PURPOSE: Recent findings have correlated neuroblastoma development with aberration of apoptosis. In particular, increased levels of survivin, a member of the inhibitor of apoptosis protein (IAP) family, have been associated with increased resistance to apoptosis in neuroblastomas. The purpose of this study was to determine whether the phosphatidylinositol 3-kinase (PI3K)/Akt pathway can alter the expression of survivin and facilitate tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in neuroblastoma cells. METHODS: Human neuroblastoma cells (SK-N-SH, BE[2]C, LAN-1 and IMR-32) were treated with LY294002 or wortmannin, inhibitors of PI3K, for 24 hours. Transient transfection of a dominant negative PI3K expression plasmid, pCGNN-Deltap85, was performed to inhibit PI3K activation. Cells were treated with TRAIL, caspase-3, or pan-caspase inhibitors. RNase protection assay was performed to assess mRNA changes in IAP family members, including survivin. Western blot analysis was performed to measure changes in the levels of procaspases and survivin. Apoptosis was assessed by a DNA fragmentation ELISA assay. RESULTS: The authors found that survivin and cIAP1 mRNA as well as protein expression were decreased after PI3K inhibition. Combination treatment with LY294002 and TRAIL increased apoptosis of SK-N-SH cells compared with TRAIL alone; these results were further corroborated by complete inhibition of apoptosis by caspase-3 or pan-caspase inhibitor. CONCLUSIONS: The authors report that PI3K pathway inhibition down-regulates survivin expression and enhances TRAIL-mediated apoptosis in neuroblastomas. PI3K pathway may play a crucial role in neuroblastoma cell survival; therefore, treatment with inhibitors of PI3K may provide potential novel therapeutic options.

Androstadienes↗
PubMed2003

Effect of ileocolonic transposition on gut morphology, gene expression, and function.

Intestinal morphology and expression of brush border enzymes can be dramatically altered by nutrient composition and position along the longitudinal gut axis. In contrast, endocrine gene expression appears to be relatively "imprinted" and is not significantly altered by positional changes. The purpose of our study was to assess the effects of transposing the ileum into the colonic position on intestinal morphology, gene expression, and enzyme activity. For this study, male Sprague-Dawley rats underwent either transposition of an approximately 8-cm segment of distal ileum into the colonic position or sham operation. Rats were sacrificed 2 months after operation and transposed or sham ileum was assessed. We found that transposition of the ileum to the colonic position resulted in no change in the ileal mucosal architecture. Furthermore, no change in the expression of the endocrine genes neurotensin and PYY or the apoptotic genes was detected. Although sucrase-isomaltase activity was decreased in the transposed ileum, this decrease did not achieve statistical significance. These results demonstrate that the ileum can be successfully interposed into the colonic position. In this location, the ileum functions normally without changes in the villus morphology or gene expression pattern despite the change in position and composition of the luminal content.

Animals↗
PubMed2003

Effect of aging on the adaptive and proliferative capacity of the small bowel.

Our society is aging at a rapid rate; the effects of aging on physiologic functions (e.g., small bowel adaptation) are poorly understood. The purpose of this study was to determine the ability of the aged small bowel mucosa to adapt after resection. Young (2-month-old) and aged (24-month-old) F344 rats underwent massive (70%) proximal small bowel resection (SBR) or sham operation; rats were killed at 9 or 16 days after surgery. The remnant small bowel and corresponding sham segments were harvested, weighed, and analyzed for DNA content and villus height. To determine whether the adaptive response after SBR could be enhanced, aged rats underwent SBR or sham operation and were treated with either neurotensin or saline solution (control). SBR resulted in adaptive hyperplasia in the remaining small bowel remnant in both young and aged rats at 9 and 16 days compared with sham animals. At 9 days, significant increases were noted in weight, villus height, and DNA content of the distal remnant in young and aged rats after SBR; the increases were similar in both young and aged rats. At 16 days, both young and aged rats displayed significant increases in remnant weight after SBR. Administration of neurotensin increased the weight of the remnant intestine in aged rats after SBR compared with saline treatment. Our findings demonstrate that aged small bowel mucosa exhibits a proliferative and adaptive capacity in response to SBR that was similar to that of the young animals. In addition, neurotensin administration enhanced the normal adaptive response of the small bowel in aged rats, providing further evidence that neurotensin may be therapeutically useful to augment mucosal regeneration in the early periods after massive SBR.

Adaptation, Physiological↗
PubMed2003

Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues.

Gastrointestinal (GI) hormones are chemical messengers that regulate the physiological functions of the intestine and pancreas, including secretion, motility, absorption, and digestion. In addition to these well-defined physiological effects, GI hormones can stimulate proliferation of the nonneoplastic intestinal mucosa and pancreas. Furthermore, in an analogous fashion to breast and prostate cancer, certain GI cancers possess receptors for GI hormones; growth can be altered by administration of these hormones or by blocking their respective receptors. The GI hormones that affect proliferation, either stimulatory or inhibitory, include gastrin, cholecystokinin, gastrin-releasing peptide, neurotensin, peptide YY, glucagon-like peptide-2, and somatostatin. The effects of these peptides on normal and neoplastic GI tissues will be described. Also, future perspectives and potential therapeutic implications will be discussed.

Cell Division↗
PubMed2002

Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death.

BACKGROUND: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor family, selectively induces apoptosis in various cancer cells; however, certain cancers can evade TRAIL-mediated apoptosis. FLICE-like inhibitory protein (FLIP), an inhibitor of caspase-8, (also known as FLICE) is regulated by the transcription factor nuclear factor-kappaB (NF-kappaB) and can contribute to TRAIL resistance. The purpose of our study was to determine whether inhibition of NF-kappaB can enhance TRAIL-mediated pancreatic cancer cell death and decrease FLIP levels. METHODS: The human pancreatic cancer cell lines MIA PaCa-2 and L3.6 were treated with TRAIL, NEMO-binding domain (NBD) peptide (a novel selective NF-kappaB inhibitor), or a combination of both. Cell viability and apoptosis were measured. Gel mobility shift assays were performed to assess NF-kappaB binding activity. Western blots were performed to assess FLIP levels after treatment with NBD or infection with an adenovirus encoding mutated IkappaBalpha. RESULTS: The aggressive L3.6 cell line was resistant to TRAIL treatment, whereas MIA PaCa-2 cells were sensitive to TRAIL. The combination of TRAIL and NBD significantly decreased cell viability and increased apoptosis in L3.6 cells. Cellular levels of FLIP were decreased by inhibition of NF-kappaB (either by NBD treatment or mutant IkappaBalpha infection). CONCLUSIONS: Our findings demonstrate resistance of the aggressive L3.6 pancreatic cell line to TRAIL treatment alone; inhibition of NF-kappaB by NBD increased TRAIL-mediated cell death and decreased FLIP protein levels. Novel agents that selectively target the NF-kappaB pathway may be useful adjuvant therapies for chemoresistant pancreatic cancers.

Apoptosis↗
PubMed2002

Activation of conventional PKC isoforms increases expression of the pro-apoptotic protein Bad and TRAIL receptors.

BACKGROUND: Pancreatic cancer is a leading cause of cancer death worldwide; current treatment options have been ineffective in prolonging survival. Agents that target specific signaling pathways (e.g., protein kinase C [PKC]) may regulate apoptotic gene expression rendering resistant cancers sensitive to the effects of other chemotherapeutic drugs. The purpose of our study was to assess the effect of PKC stimulation on apoptotic gene expression in pancreatic cancer cells. METHODS: The human pancreatic cancer cell line, PANC-1, was treated with PKC-stimulating agents, phorbol 12-myristate 13-acetate (PMA) or bryostatin-1, and analyzed for expression of apoptosis-related genes. RESULTS: Both PMA and bryostatin-1 induced expression of the pro-apoptotic gene Bad in a dose dependent fashion. The expression of Bad was blocked by the PKC inhibitors GF109203x, Gö6983, and Ro-31-8220, suggesting a role for the conventional isoforms of PKC. In addition, treatment with the MEK inhibitors PD98059 or UO126 reduced PMA-mediated induction of Bad gene expression. PMA also increased the expression of TRAIL receptors DR4 and DR5; this expression was inhibited by the PKC inhibitors GF109203x, Gö6983, and Ro-31-8220 and the MEK inhibitor UO126, suggesting a role for conventional PKC isoforms and MEK in the regulation of TRAIL receptor expression. CONCLUSIONS: PKC stimulation in PANC-1 cells increases expression of the pro-apoptotic gene Bad and the TRAIL receptors, DR4 and DR5, through both conventional PKC- and MEK-dependent pathways. Agents that stimulate PKC may sensitize pancreatic cancer cells to apoptosis and provide a potential adjuvant therapy for the treatment of chemoresistant pancreatic cancers.

Apoptosis↗
PubMedDate not supplied

Age-associated changes in gene expression patterns in the liver.

Aging is one of the least clearly understood biological processes. Alteration of oxidation/reduction (redox) enzymes has been demonstrated with aging; however, a systematic analysis of expression patterns has not been performed. The liver plays a key role in homeostasis and detoxification; therefore alteration of hepatic gene expression with aging may affect outcome after surgery. The purpose of our study was to assess changes in gene expression patterns in aged livers from both rats and humans using gene array analysis. Total RNA was extracted from young (2-month-old) and aged (2-year-old) rat livers, as well as young (1-year-old) and aged (78-year-old) human livers. Gene expression patterns were compared using Affymetrix GeneChip arrays. The expression pattern of selected genes was confirmed by reverse transcription-polymerase chain reaction. A threefold or greater change in gene expression was noted in 582 genes in the aged rat livers and 192 genes in the aged human livers. Comparison of the genes that were increased with aging demonstrated some similar patterns of expression in the rat and human livers, particularly in members of the antioxidant family and the cytochrome P-450 genes. Our findings demonstrate changes in the expression pattern of genes in the liver with aging. Concomitant increases in the expression of important antioxidant and detoxifying genes were noted in the livers of both rats and humans. This induction pattern suggests a complex link between changing hepatic detoxification/redox capability and senescence.

Aged↗